This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ADVM Adverum Biotechnologies (ADVM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Adverum Biotechnologies Stock (NASDAQ:ADVM) Get ADVM alerts:Sign Up Key Stats Today's Range$4.36▼$4.3650-Day Range$4.09▼$4.3652-Week Range$1.78▼$5.75VolumeN/AAverage Volume452,470 shsMarket Capitalization$96.26 millionP/E RatioN/ADividend YieldN/APrice Target$10.50Consensus RatingHold Company Overview Adverum Biotechnologies is a clinical-stage gene therapy company focused on the discovery, development and delivery of novel treatments for ocular and rare diseases. Utilizing adeno-associated virus (AAV)–based vectors, the company seeks to deliver long-lasting, one-time therapies designed to address underlying genetic causes of vision loss and other conditions. Its proprietary platform combines engineering of AAV capsids for targeted tissue tropism with optimized expression cassettes, aiming to improve safety and durability over current standards of care. The company’s lead programs target retinal disorders, including wet age-related macular degeneration (wet AMD) and diabetic retinopathy, through intravitreal administration of AAV vectors expressing therapeutic proteins. Key pipeline candidates include ADVM-022, which delivers a gene encoding an anti-VEGF molecule, and ADVM-043, a next-generation vector designed for broad ocular neovascular indications. Preclinical efforts also explore additional ophthalmic and rare disease targets, leveraging Adverum’s vector design expertise to expand into conditions with significant unmet medical need. Adverum conducts research and clinical development primarily in the United States, with trial sites and regulatory engagement extending into Europe and other regions. The company collaborates with academic institutions, contract research organizations and strategic partners to advance its programs through Phase 1 and Phase 2 studies. Manufacturing and supply chain activities are supported by external GMP-compliant facilities, enabling scalable vector production for both clinical and future commercial use. Founded in 2006 (formerly known as Avalanche Biotechnologies), Adverum Biotechnologies has evolved through multiple financing rounds and a 2019 corporate rebranding to reflect its broadened gene therapy ambitions. The company is led by President and Chief Executive Officer Adie Kim, whose background in specialty pharmaceuticals and biotech supports Adverum’s transition from early research to late-stage clinical development. Through its focused platform and strategic collaborations, Adverum aims to deliver durable, potentially curative treatments that could transform care for patients with vision disorders and other genetic diseases.AI Generated. May Contain Errors. Read More Adverum Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreADVM MarketRank™: Adverum Biotechnologies scored higher than 23% of companies evaluated by MarketBeat, and ranked 771st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAdverum Biotechnologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.Upside PotentialAdverum Biotechnologies has a consensus price target of $10.50, representing about 140.8% upside from its current price of $4.36.Amount of Analyst CoverageAdverum Biotechnologies has received no research coverage in the past 90 days.Read more about Adverum Biotechnologies' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($4.92) to ($5.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdverum Biotechnologies has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ADVM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have not sold or bought any company stock.Percentage Held by Insiders6.00% of the stock of Adverum Biotechnologies is held by insiders.Percentage Held by Institutions48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adverum Biotechnologies' insider trading history. Receive ADVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADVM Stock News HeadlinesHedge Fund and Insider Trading News: Cathie Wood, Michael Burry, Renaissance Technologies, Mason Capital, Millennium Management, Adverum Biotechnologies Inc (ADVM), MGM Resorts ...December 12, 2025 | insidermonkey.comMonday’s Insider Moves: Adverum Execs Lead Buys, Diamondback Sale TopsDecember 9, 2025 | investing.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 21 at 1:00 AM | Brownstone Research (Ad)Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisitionDecember 9, 2025 | prnewswire.comAdverum Biotechnologies (ADVM) price target decreased by 50.51% to 5.00December 6, 2025 | msn.comAdverum Biotechnologies releases promising phase 2 trial dataDecember 4, 2025 | msn.comAdverum Biotechnologies reminds stockholders to tender their sharesDecember 1, 2025 | msn.comAdverum Reminds Stockholders to Tender their Shares into the Offer by LillyDecember 1, 2025 | globenewswire.comSee More Headlines ADVM Stock Analysis - Frequently Asked Questions How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies, Inc. (NASDAQ:ADVM) issued its quarterly earnings data on Wednesday, November, 12th. The biotechnology company reported ($2.03) earnings per share for the quarter, missing the consensus estimate of ($1.80) by $0.23. When did Adverum Biotechnologies' stock split? Shares of Adverum Biotechnologies reverse split before market open on Thursday, March 21st 2024.The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Adverum Biotechnologies IPO? Adverum Biotechnologies (ADVM) raised $99 million in an initial public offering (IPO) on Thursday, July 31st 2014. The company issued 6,000,000 shares at $16.00-$17.00 per share. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adverum Biotechnologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings11/12/2025Today5/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADVM CIK1501756 Webwww.adverum.com Phone(650) 656-9323Fax650-329-8151Employees190Year Founded2006Price Target and Rating Average Price Target for Adverum Biotechnologies$10.50 High Price Target$33.00 Low Price Target$4.00 Potential Upside/Downside+140.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($8.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.93 million Net MarginsN/A Pretax Margin-16,949.20% Return on Equity-3,476.17% Return on Assets-152.07% Debt Debt-to-Equity RatioN/A Current Ratio0.65 Quick Ratio0.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.40 per share Price / Book1.28Miscellaneous Outstanding Shares22,077,000Free Float20,752,000Market Cap$96.26 million OptionableOptionable Beta0.87 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ADVM) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
